A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, With a Lorazepam Arm, in Subjects With Generalized Anxiety Disorder (GAD).
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2010
At a glance
- Drugs AZD 7325; Lorazepam
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Sep 2009 Actual patient number (677) added as reported by ClinicalTrials.gov.
- 11 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.